Potential future therapies for psoriasis.
Papp
K Alexander
KA
Probity Medical Research, and University of Western Ontario, London, Ontario, Canada. kapapp@probitymedical.com
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005544:Forecasting; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D009539:Nicotinic Acids / Q000627:therapeutic use; D011565:Psoriasis / Q000628:therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D053319:Tumor Necrosis Factor Decoy Receptors; D000069549:Ustekinumab; D012176:Retinoids
D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D016572:Cyclosporine; D003879:Dermatologic Agents; D005650:Fumarates; D000069285:Infliximab; D009539:Nicotinic Acids; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D016559:Tacrolimus; D053319:Tumor Necrosis Factor Decoy Receptors; D000069549:Ustekinumab; C069521:recombinant human tumor necrosis factor-binding protein-1; C484071:voclosporin; C117268:pimecrolimus; C086827:tazarotene; D012176:Retinoids; C032005:fumaric acid